Home › Companies › EVMN

Evommune

Market cap $290M 41.3M shares (10-Q, Nov 10, 2026) × $7.02 close Nov 17, 2026

Most recent annual filing: 2026-03-15

Catalyst timeline

5 trackedQuarter catalyst calendar →
  1. EVO301 corporate update2H 2026EVO301 corporate update, 2H 2026, routine
  2. EVO570 corporate update~Jan 2027EVO570 corporate update, ~Jan 2027, routine
  3. EVO301 Ph2b startMid-2027EVO301 Ph2b start, Mid-2027, routine
  4. EVO756 toplineJul 16, 2027EVO756 topline, Jul 16, 2027, major
  5. EVO646 Ph1 readoutLate 2027EVO646 Ph1 readout, Late 2027, notable

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (6 active programs)

Technology platforms

SAFAbody · AprilBio Co., Ltd.

SAFA (Anti-Serum Albumin Fab-Associated) fusion protein platform enabling half-life extension via FcRn-mediated recycling of human serum albumin and efficient tissue distribution due to smaller molecular size (~65 kDa); used to engineer EVO301 as a long-acting IL-18BP therapeutic for inflammatory diseases including atopic dermatitis and ulcerative colitis

Targets: IL-18BP, HSA

Discontinued (2)

Capital (as filed)

Cash
$47.6M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$121M Sep 30, 2026
Long-term investments
$93.6M Sep 30, 2026
Operating cash flow
−$25.9M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$262M cash, runway 2H 2029 per the update of Nov 12, 2026 — the company's own words as read there, not the filed figure

Offering documents (5)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (7)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (7 calls)

Every verdict Biotech Distilled has published on Evommune, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Watch Evommune (EVMN) — Scientific Deep Dive for EVO756, EVO301 and Pipeline Products Strong science and smart-money cap table, but the June CSU binary is too high-risk to size into without pre-binary trim discipline, and licensed economics cap upside.
  2. Avoid UPDATE: Evommune (EVMN) — The CSU Shot Misses EVO756 missed the CSU primary endpoint at every dose, zeroing the lead value driver; mechanism failed its cleanest randomized test and read-across to remaining indications is now negative.
  3. Avoid UPDATE: Evommune (EVMN) - The Clock Moves Up to September AD readout dated for September but mechanism failed its cleanest test, dose ceiling keeps falling, and no catalyst justifies re-entry ahead of the print.
  4. Avoid UPDATE: Evommune (EVMN) - The Second Shot Misses Too EVO756 missed AD primary and all secondaries at every dose; two randomized Phase 2b failures confirm a mechanism story not a dose story, leaving only a lottery-ticket migraine trial and EVO301 a year from data.
  5. Watch UPDATE: Evommune (EVMN) - The Last Shot Standing Shows Its Numbers EVO301 posted a statistically clean placebo-controlled EASI signal at EADV with consistent secondaries and clean safety, while the stock trades near cash, making the pipeline effectively free.
  6. Watch UPDATE: Evommune (EVMN) - A Third Shot, Paid for in Shares In-licensing EVO570 (VAV1 molecular glue degrader) broadens the pipeline cheaply but adds a preclinical asset with no human data; stock still trades near cash so watch list is maintained without upgrade.
  7. Watch UPDATE: Evommune (EVMN) - The Cash Floor Gets Left Behind Q3 cash confirmed and Phase 2b design disclosed, but the stock has run 33% above the PIPE price and now prices in pipeline value, reducing the margin of safety that made the watch-list setup compelling.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (3 quotes from 3 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (42)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Jul 30, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

10 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)